Back Matter
Harnessing MerTK agonism for targeted therapeutics
Vivekananda Kedagea Department of Molecular Oncology, Genentech, South San Francisco, CA, USA
https://orcid.org/0000-0001-9991-3245
https://orcid.org/0000-0001-9991-3245, , Yongmei Chenc Department of Antibody Engineering, Genentech, South San Francisco, CA, USAhttps://orcid.org/0000-0002-4696-0782
https://orcid.org/0000-0002-4696-0782, Wei-Ching Liangc Department of Antibody Engineering, Genentech, South San Francisco, CA, USAhttps://orcid.org/0000-0002-4082-6881
https://orcid.org/0000-0002-4082-6881, Joven Borneod Department of Immunology and Infectious Diseases, Genentech, South San Francisco, CA, USAhttps://orcid.org/0000-0002-6956-6913
https://orcid.org/0000-0002-6956-6913, & Minhong Yana Department of Molecular Oncology, Genentech, South San Francisco, CA, USACorrespondence[email protected]
https://orcid.org/0000-0001-6126-9714
https://orcid.org/0000-0001-6126-9714 show all